theMednetRegister

Gastroenterology

Cancer Prevention   

Questions discussed in this category

How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?
Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should...
1 Answer available


Papers discussed in this category

BMC endocrine disorders, 2024 Nov 18
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.
International urology and nephrology, 2024 Nov 04
Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.
Cancers, 2024 Sep 22
Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.

Related Topics in Gastroenterology

Copyright © 2025 theMednet
All Rights Reserved.